Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc (KNSA) reported that its chief medical officer, John F. Paolini, received equity awards and had previously granted RSUs vest on September 1, 2026. He was granted 6,700 Restricted Share Units, each representing one Class A Ordinary Share, vesting in four annual installments starting September 1, 2026, and a share option for 26,750 Class A Ordinary Shares at an exercise price of $79.28 per share, expiring August 31, 2036, with vesting beginning September 1, 2026. On the same date, RSUs from earlier grants dated September 1, 2022, 2023, 2024, and 2025 vested, resulting in the exercise or conversion of 8,328 RSUs into Class A Ordinary Shares. Of the shares issued upon these vestings, 4,029 Class A Ordinary Shares were delivered or withheld at $79.28 per share for payment of exercise price or tax liability. No Rule 10b5-1 trading plan is reported for these transactions.
Kiniksa Pharmaceuticals International, plc (KNSA) reported that Chief Operating Officer Ross Moat received equity awards and exercised existing awards on September 1, 2026. He was granted 9,250 Restricted Share Units, plus a Share Option for 36,950 Class A Ordinary Shares at an exercise price of $79.28. Several prior RSU grants totaling 8,285 units were exercised into the same number of Class A Ordinary Shares, and 4,007 shares were delivered or withheld to pay the option exercise price or tax liability. The new RSUs and options generally vest over four years starting on September 1, 2026, with 25% vesting on the first anniversary and the remainder in subsequent installments. No Rule 10b5-1 trading plan is reported.
Kiniksa Pharmaceuticals International, plc (KNSA) disclosed that Chief Accounting Officer Michael R. Megna reported multiple equity transactions. On September 3, 2026, he sold 4,600 Class A Ordinary Shares at $80.30 per share under a Rule 10b5-1 trading plan executed on May 24, 2025. On September 1, 2026, he received a grant of 3,650 Restricted Share Units and a grant of 14,600 share options exercisable at $79.28 per share, plus several RSU conversions into Class A Ordinary Shares and a disposition of 5,531 shares at $79.28 for payment of exercise price or tax liability. He also voluntarily reported acquiring 279 shares at $33.50 on July 15, 2026 under the 2018 Employee Share Purchase Plan.
Kiniksa Pharmaceuticals International, plc (KNSA) has a notice of proposed sale under Rule 144 by officer Michael R. Megna for up to 4,600 Class A ordinary shares of Kiniksa, to be sold through Charles Schwab & Co., Inc.
The filing lists an aggregate market value of $369,380.00 for these shares and states that 48,289,273 Class A ordinary shares were outstanding at the referenced time; this is a baseline figure, not the amount being sold. The shares to be sold relate to a restricted stock lapse on September 1, 2026, categorized as equity compensation.
Kiniksa Pharmaceuticals International, plc (KNSA) director Barry D. Quart reported a bona fide gift of 2,600 Class A Ordinary Shares on 2026-08-19. The gift transferred shares at a reported price of $0.00 per share to a donor advised fund. Following this transaction, Quart directly holds 12,745 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc director Richard S. Levy received an award of 403 Restricted Share Units on August 1, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share and vested immediately upon grant. The RSUs were then exercised and converted into 403 Class A Ordinary Shares, bringing his direct holdings to 22,359 shares, with no share sales reported.
Cole G Bradley, a director of Kiniksa Pharmaceuticals International, plc, reported two share dispositions on 29 July 2026. He sold 3,673 Class A Ordinary Shares at $81.43 per share and made a bona fide gift of 4,500 shares to a donor advised fund. The Rule 10b5-1 trading plan box was not checked.
Kiniksa Pharmaceuticals International, plc submitted a notice covering potential sales of Class A Ordinary Shares under Rule 144. The filing ties shares to an employee stock option exercise dated July 29, 2026 involving 45,049 shares, and to equity compensation (PSU/RSU) from March 16, 2022 involving 22,013 shares, with Charles Schwab & Co., Inc. listed as broker.
Kiniksa Pharmaceuticals, Ltd. has a holder planning to sell 3,673 Class A ordinary shares under Rule 144 through Charles Schwab & Co., Inc. The shares have an aggregate market value of $299,092.00. Class A ordinary shares outstanding were 48,289,273 and are listed on NASDAQ.
Recent equity compensation-related activity includes restricted stock lapses of 500 shares on June 29, 2023 and 3,173 shares on June 5, 2025.
BlackRock, Inc. reports beneficial ownership of common stock of Kiniksa Pharmaceuticals International, plc. BlackRock and certain of its business units beneficially own 2,534,789 shares of Kiniksa common stock, representing 5.5 % of the outstanding class as of the reporting date.
BlackRock has sole voting power over 2,470,912 shares and sole dispositive power over 2,534,789 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends and sale proceeds, but no single such person has more than five percent of Kiniksa’s total outstanding common shares.